The Cutting Edge of Psoriasis Research
Treatment Goals
Protein Targets
IL-17 Blockers
IL-23 Blockers
Gene-Based Gels
Turmeric
Sleep
Weight Loss
Depression
Meds and Light Therapy
Smoking
Heart Disease
Bone Loss
Healing Genes
Safer Treatments
Show Sources
SOURCES:
National Psoriasis Foundation: “Can't sleep? Psoriasis, psoriatic arthritis may be to blame,” “Depression,” “Healing power of a protein could help psoriasis,” “Herbs/Natural Remedies,” “Link found between osteoporosis and psoriasis, psoriatic arthritis,” “Moderate to Severe Psoriasis and Psoriatic Arthritis: Biologic Drugs,” “The link between psoriatic disease and mental illness,” “Treat to Target,” “Trial drug shows small target can improve psoriasis," "What We Are Learning About Psoriasis and Heart Disease," "FDA Approves Stelara® for Pediatric Psoriasis Patients," "Psoriasis Guidelines."
Journal of the American Academy of Dermatology: “From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis," "Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures."
Nature Communications: “IL-12 protects from psoriasis from skin inflammation.”
The New England Journal of Medicine: “A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis,” “Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.”
News release, University of Zurich.
News release, Northwestern University Feinberg School of Medicine.
News release, FDA.
ClinicalTrials.gov: “BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis,” “Sleep, Circadian Rhythm & Skin Health.”
News release, Nasdaq.
Science: “Spherical RNA therapy shows promise against psoriasis in first human trial.”
Iranian Journal of Pharmaceutical Research: “Topical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation.”
American College of Rheumatology: “Clinical Improvements in Psoriasis and Psoriatic Arthritis with Surgical Weight Loss.”
NYU Langone Medical Center: “Psoriasis & Psoriatic Arthritis Symptoms Curbed by Bariatric Surgery.”
JAMA Dermatology: “Psoriasis and the Risk of Depression in the US Population.”
Lancet: “Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.”
Psoriasis: Targets and Therapy: “Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability.”
The Biochemical Journal: “Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-κB activation.”
Arteriosclerosis, Thrombosis, and Vascular Biology: “Nationwide Study on the Risk of Abdominal Aortic Aneurysms in Patients With Psoriasis,” “Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study.”
Journal of Dermatology: “Psoriasis and bone mineral density: implications for long-term patients.”
Science Translational Medicine: “Chronic skin inflammation leads to bone loss by IL-17–mediated inhibition of Wnt signaling in osteoblasts.”
News release, Spanish National Cancer Research Centre.
The Journal of Clinical Investigation: “A GRHL3-regulated repair pathway suppresses immune-mediated epidermal hyperplasia,” “RAC1 activation drives pathologic interactions between the epidermis and immune cells.”
News release, Stanford Medicine.
Frontiers in Immunology: "Impact of Chronic Inflammation in Psoriasis on Bone Metabolism."
Medscape: "Oral IL-23 Receptor Antagonist for Psoriasis Promising: Phase 2b Study."
Expert Opinion on Biological Therapy: "Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations."
Psoriasis: Targets & Therapy: "Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability."
FDA: "FDA approves new psoriasis drug."
Sec.gov: "Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis."
Frontiers in Pharmacology: "Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms."
Cureus: "Association Between Psoriasis and Depression: A Traditional Review."